It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
N6-methyladenosine (m6A) is the most common and abundant RNA modification. Recent studies have shown its importance in the regulation of several biological processes, including the immune response, and different approaches have been developed in order to map and quantify m6A marks. However, site specific detection of m6A methylation has been technically challenging, and existing protocols are long and tedious and often involve next-generation sequencing. Here, we describe a simple RT-QPCR based approach for the relative quantification of candidate m6A regions that takes advantage of the diminished capacity of BstI enzyme to retrotranscribe m6A residues. Using this technique, we have been able to confirm the recently described m6A methylation in the 3′UTR of SOCS1 and SOCS3 transcripts. Moreover, using the method presented here, we have also observed alterations in the relative levels of m6A in specific motifs of SOCS genes in celiac disease patients and in pancreatic β-cells exposed to inflammatory stimuli.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of the Basque Country (UPV-EHU), Biocruces-Bizkaia Health Research Institute, Department of Genetics, Physical Anthropology and Animal Physiology, Leioa, Spain (GRID:grid.11480.3c) (ISNI:0000000121671098); IKERBASQUE, Basque Foundation for Science, Bilbao, Spain (GRID:grid.424810.b) (ISNI:0000 0004 0467 2314); Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain (GRID:grid.424810.b)
2 University of the Basque Country (UPV-EHU), Endocrinology and Diabetes Research Group, Biocruces-Bizkaia Health Research Institute, Department of Biochemistry and Molecular Biology, Leioa, Spain (GRID:grid.11480.3c) (ISNI:0000000121671098); Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain (GRID:grid.11480.3c)
3 University of the Basque Country (UPV-EHU), Biocruces-Bizkaia Health Research Institute, Department of Genetics, Physical Anthropology and Animal Physiology, Leioa, Spain (GRID:grid.11480.3c) (ISNI:0000000121671098)
4 Cruces University Hospital, University of the Basque Country (UPV-EHU), Pediatric Gastroenterology Unit, Barakaldo, Spain (GRID:grid.411232.7) (ISNI:0000 0004 1767 5135)
5 University of the Basque Country (UPV-EHU), Biocruces-Bizkaia Health Research Institute, Department of Genetics, Physical Anthropology and Animal Physiology, Leioa, Spain (GRID:grid.11480.3c) (ISNI:0000000121671098); Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain (GRID:grid.11480.3c)




